In conjunction with the Chicago Medical Society,
The Chicago Urological Society Presents

Prostate Cancer: From Active Surveillance to Locally Advanced/ Oligometastatic Disease Updates in Management Across the Disease Spectrum

12/05/2018

University Club of Chicago

Keynote Lecture: H. Ballentine Carter, MD
Johns Hopkins University
Program Chair: Edward Schaeffer, MD, PhD
Co-Chair: Greg Auffenberg, MD

This live activity is designated for a maximum of 3.50 AMA PRA Category 1 Credit(s)™

Target Audience: Urologists

EDUCATIONAL NEEDS

There have been significant advances in our understanding of the screening for, diagnosis of and treatment of prostate cancer in the last year. Specifically there have been discoveries in germline genetics that impact how we screen men with family histories of prostate, breast, ovarian and pancreatic cancers. Additionally new randomized trials have revealed novel ways to screen men for prostate cancer and to treat advanced and recurrent prostate cancer. With all these novel discoveries in mind, this session aims to improve the practice of prostate cancer management.

DESIRED LEARNING OUTCOMES

At the conclusion of this meeting, the attendee should be able to:

1. Describe recent discoveries in genetics that impact how we screen and treat prostate cancer.

2. Describe recent advances in imagining that impact how we screen for prostate cancer

3. Understand and improve limitations to utilizing active surveillance across all practice types

4. Understand and improve utilization of post-operative radiation for localized prostate cancer

5. Understand what oligo metastatic prostate cancer is and how urologist can better identify and treat it.

6. Understand novel treatments for advanced prostate cancer and the role the Urologist plays in its treatment

7. Process and implement advances in active surveillance based on over two decades of work. Lessons learned from Johns Hopkins Active Surveillance program.

CME INFORMATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Chicago Medical Society and the Chicago Urological Society. The Chicago Medical Society is accredited by the ACCME to provide continuing medical education for physicians.

The Chicago Medical Society designates this live activity for a maximum of **3.50** ***AMA PRA Category 1 Credit(s)™.*** Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY LIST

Briand Helfand, MD, PhD
Director of Prostate Cancer
NorthShore University
Chicago, Illinois

Dr. Helfand has disclosed that he has received an honorarium as a speaker for Ambry Genetics.

Scott Eggener, MD
Director of Prostate Cancer
University of Chicago
Chicago, Illinois

Dr. Eggener has disclosed that he has received an honorarium from Insightec, Profound Medical, Omnecoil and Janssen for being an advisor and consultant.

Greg Auffenberg, MD
Assistant Professor, Urology
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Dr. Auffenberg has disclosed that he does not have any relevant financial relationships with commercial interests.

Daniel Spratt, MD
Chief of the Genitourinary Radiotherapy Program
University of Michigan
Ann Arbor, Michigan

Dr. Spratt has disclosed that he does not have any relevant financial relationships with commercial interests.

Edward Schaeffer, MD, PhD
Chair, Department of Urology
Northwestern University
Chicago, Illinois

Dr. Schaeffer has disclosed that he has received a consulting fee and honorarium for being a consultant and on the advisory board for Opko Health, Abbvie and GenomeDX

Maha Hussain, MD
Professor of Medicine, Hematology and Oncology
Northwestern University
Chicago, Illinois

Dr. Hussain has disclosed that she has received an honorarium and received research support for being on the advisory board, and a lecturer for Pfizer, Sanofi, Genetech, AZ and Bayer .

H. Ballentine Carter, MD
Director, The Prostate Cancer Program
Johns Hopkins School Of Medicine
Baltimore, Maryland

Dr. Carter has disclosed that he does not have any relevant financial relationships with commercial interests.

PROGRAM INFORMATION

Wednesday, December 5, 2018
Program Chair: Edward Schaeffer, MD, PhD
Co- Chair: Greg Auffenberg, MD

1:30 - 1:55 PM	What Urologist Need To Know About Cancer Brian Helfand, MD, PhD
1:55 - 2:20 PM	Are Advanced Imaging Tools Ready To Replace Prostate Biopsy in the Diagnosis and Management of the Prostate Cancer Scott Eggener, MD
2:20 - 2:45 PM	What Are the Common Hurdles and Solutions for Performing “Safe” and Reliable Active Surveillance Lessons Learned From a State Wide Registry Greg Auffenberg, MD
2:45 - 3:05 PM	Optimal Timing of Adjuvant and Salvage Radiation After Primary Surgical Intervention Daniel Spratt, MD
3:05 - 3:25 PM	Oligometastatic Prostate Cancer: What Is It? How Do We Diagnose It? And How Should We Be Treating It? Edward Schaeffer, MD, PhD
3:25 - 3:50 PM	Break*
3:50 - 4:15 PM	What Does Level One Evidence Suggest Is “Best Practice” In the Management of Biochemically Recurrent Prostate Cancer? Maha Hussain, MD
4:15 - 5:15 PM	How To Optimize Contemporary Active Surveillance. Lessons Learned From Over Two Decades of Prospective Work H. Ballentine Carter, MD
5:15 - 6:30 PM	Fellowship Hour*

* No CME credits awarded

UNIVERSITY CLUB OF CHICAGO

- Please note that the Club has a dress code of business casual to business attire.
- Restrooms are located on the first floor of the Club.
- Kindly refrain from using your cellular phones in common areas and stairways.

CLAIMING CME CREDITS

To claim your CME credits, please make sure you check in and sign in upon arrival, and complete both the pre and post surveys provided during the meeting. Your CME certificate will be mailed to you within three (3) months of the meeting date.

CME PLANNING COMMITTEE

The following planning members of the Chicago Medical Society's CME Subcommittee on Joint Providorship have disclosed that they have no relevant financial relationships with commercial interests:

Michael Hanak, MD, FAA
Eric A. Eason, MD
Arjang Khorasani, MD
Vemuri S. Murthy, MD

The following planning members of the Chicago Urological Society have disclosed that they have no relevant financial relationships with any commercial interests:

Claire Krieger, Meeting Coordinator

EXHIBITORS

PRESIDENT'S TABLE SPONSOR

Abbvie

PLATINUM SPONSORS

Astellas Oncology
Astellas Pharmaceuticals
Bayer
Genomic Health
Myriad Genetics
Pfizer
Tolmar Pharmaceuticals

GOLD SPONSORS

Boston Scientific
Coloplast
Janssen Oncology
Lumenis

SILVER SPONSORS

Allergan

BRONZE SPONSOR

Augmenix, Inc
MdX Health
Prometheus
SRS Medical

SINGLE MEETING SPONSORS

Blue Earth Dianostics
BioReference/OPKO Health
GenPath Diagnostics

The CUS would like to sincerely thank all of our Exhibitors for their participation in this event. Attendees will have the opportunity to meet with industry representatives in the designated Exhibitor area.

Next CUS Meeting:

January 9, 2019